Anaptysbio (ANAB) Research & Development (2016 - 2026)

Anaptysbio has reported Research & Development for 11 years, with the latest figure at $34.0 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development fell 17.46% year-over-year to $34.0 million; the trailing twelve-month figure through Mar 2026 stood at $128.8 million (down 23.33% YoY), and the FY2025 full-year result was $136.0 million, down 17.01% from the prior year.
• Research & Development for Q1 2026 stood at $34.0 million, up from $25.6 million in the prior quarter.
• The five-year high for Research & Development was $42.6 million in Q4 2024, with the low at $20.8 million in Q2 2022.
• Historically, Research & Development has averaged $32.6 million across 5 years, with a median of $33.5 million in 2023.
• Annual changes were most pronounced in 2023 — Research & Development surged 57.95% — and 2025, when it slumped 39.99%.
• Anaptysbio's Research & Development stood at $23.4 million in 2022, then surged by 43.43% to $33.5 million in 2023, then rose by 27.04% to $42.6 million in 2024, then slumped by 39.99% to $25.6 million in 2025, then soared by 32.99% to $34.0 million in 2026.
• The last three Research & Development figures came in at $34.0 million (Q1 2026), $25.6 million (Q4 2025), and $31.4 million (Q3 2025), per Business Quant data.